Merk — Trading Ideas on TradingView

MRK Merck Options Ahead of Earnings Analyzing the options chain and the chart patterns of MRK Merck prior to the earnings report this week, I would consider purchasing the 80usd strike price Calls with an expiration date of 2026-1-16, for a premium of approximately $8.50. If these options prove to be profitable prior to the earnings release, I would sell at least half of them.

Merk Ok this looks oversold. In fact, Oversold on multiple timeframe So here’s a technical analysis with potential price targets and trade direction: Current Market Conditions & Observations 1. Trend Direction: Bearish • The stock is in a clear downtrend, breaking multiple levels of support. • Break of Structure (BOS) labels indicate lower lows forming consistently. • A recent breakdown below support at ~$94.23 suggests further downside pressure. 2. Support & Resistance Zones: • Current support: ~$85.50 (testing support level) • Next major support: ~$80.00 (potential downside target) • Major resistance: $94.00 (previous support turned resistance) • Further resistance zones: $100 - $105 (if a reversal happens) 3. Indicators: • Stochastic RSI: Oversold territory (possible short-term relief bounce) • Volume: Elevated selling pressure, confirming the downward move. • Liquidity zones & Order Blocks: Price has entered a demand zone near $85. Trade Outlook & Price Targets • Short-Term Bearish Bias: The breakdown suggests continued downward momentum. If $85.50 breaks, next downside target is $80.00. • Possible Relief Rally: A short-term bounce could occur if buyers defend $85.50, but upside is capped at $94.00 unless strong momentum builds. • Long-Term Reversal: Would require a break back above $100-$105 to shift into a bullish structure. Trade Strategy Ideas 1. Bearish Scenario (Short Trade) • Entry: Rejection near $90-$94 zone. • Target 1: $85.50 (current support). • Target 2: $80.00 (major demand zone). • Stop-loss: Above $96.00 (invalidate bearish setup). 2. Bullish Scenario (Reversal Play) • Entry: If price holds $85.50 with strong volume. • Target 1: $94.00 (resistance). • Target 2: $100 (trend change confirmation). • Stop-loss: Below $83.00 (breaks structure). Final Outlook • Bias: Bearish unless $85.50 holds. • Short-term: Expect further downside pressure. • Medium-term: A break below $85.50 could lead to $80.00. • Long-term: Needs a reclaim above $100 to flip bullish.

Merck's New Drug for Rare High Blood Pressure Approved by FDA Merck & Co., ( NYSE:MRK ) has achieved a significant milestone in the realm of medical innovation with the recent approval of its groundbreaking treatment for a rare and life-threatening form of high blood pressure. The approval of the drug, known as sotatercept and to be marketed as Winrevair in the US, by the Food and Drug Administration (FDA) marks a pivotal moment not only for Merck but also for patients suffering from pulmonary arterial hypertension (PAH). Let's delve deeper into the implications of this milestone and its potential impact on both Merck and the medical landscape. Addressing a Critical Need: PAH, characterized by dangerously elevated blood pressure in the lungs, poses a significant health threat to thousands of Americans, particularly among the elderly, women, and Black individuals. Despite existing therapies, many patients fail to respond adequately, highlighting the urgent need for innovative treatment options. Merck's Winrevair offers a promising solution, providing hope for improved outcomes and quality of life for PAH patients. A Game-Changer in PAH Treatment: Experts have hailed Merck's drug as potentially groundbreaking in the treatment of PAH. With its demonstrated efficacy in clinical trials, including significant improvements in patients' ability to walk and perform daily activities, Winrevair represents a paradigm shift in PAH management. Moreover, its approval for self-administration offers added convenience and flexibility for patients, further enhancing its appeal and accessibility. Strategic Implications for Merck: The approval of Winrevair comes at a critical juncture for Merck as it navigates the evolving pharmaceutical landscape. With the looming expiration of market exclusivity for its blockbuster drug Keytruda, Merck has been seeking innovative therapies to diversify its portfolio and sustain long-term growth. Winrevair's potential to generate multibillion-dollar revenues and fill the gap left by Keytruda underscores its strategic importance for Merck's future success. Market Response and Outlook: Investors have responded positively to the news of Winrevair's approval, driving a surge in Merck's stock price. Analysts have revised their sales projections upwards, reflecting confidence in the drug's commercial potential and its ability to address unmet medical needs. Moreover, ongoing research into Winrevair's long-term benefits and potential expansion into new patient populations bodes well for its sustained growth and market penetration.

Merck's Keytruda Triumphs in Q4 Reports Merck & Co ( NYSE:MRK ) has emerged victorious in its fourth-quarter performance, exceeding market expectations fueled by the remarkable success of its flagship cancer immunotherapy drug, Keytruda. The pharmaceutical giant reported robust financials, driven by a 21% surge in Keytruda sales, catapulting it to the status of the world's best-selling prescription medicine. This stellar performance not only defied analyst predictions but also positioned Merck ( NYSE:MRK ) as a frontrunner in the pharmaceutical industry. Keytruda's Stellar Performance: Keytruda's sales reached an impressive $6.6 billion in Q4, outpacing estimates and contributing to a total annual revenue of $25 billion. The drug's success is attributed to Merck's strategic efforts to expand its usage in earlier stage cancers. Despite its impending patent expiration by the end of the decade, Keytruda remains a formidable asset for Merck ( NYSE:MRK ), overshadowing even the peak sales of AbbVie's blockbuster arthritis drug, Humira. Strategic Moves to Counter Patent Exclusivity Loss: Aware of the looming patent exclusivity loss, Merck ( NYSE:MRK ) has proactively engaged in strategic initiatives to mitigate the impact. The pharmaceutical giant recently entered into multiple deals, including a significant $5.5 billion collaboration with Japan's Daiichi Sankyo for the co-development of three promising cancer drugs. These moves signify Merck's commitment to maintaining its competitive edge and market leadership in the evolving pharmaceutical landscape. Optimistic Outlook and Pipeline Expansion: Merck ( NYSE:MRK ) has revised its outlook for the mid-2030s, projecting adjusted annual sales for new oncology products to exceed $20 billion, up from the initial estimate of over $10 billion. The company has similarly elevated its mid-2030s forecast for cardiometabolic products to approximately $15 billion, demonstrating confidence in the potential of its diversified portfolio. Financial Resilience and Restructuring Efforts: Despite taking a charge of $1.69 a share related to the Daiichi deal, Merck ( NYSE:MRK ) reported adjusted earnings of 3 cents per share in Q4, defying expectations of an 11 cents per share loss. The company's Q4 revenue of $14.6 billion, a 6% increase from estimates, further underscores its financial resilience. Merck has also initiated a restructuring program aimed at optimizing manufacturing operations for both human and animal health, projecting completion by the end of 2031. While this program incurs approximately $4 billion in cumulative pre-tax costs, Merck's proactive stance signals a commitment to long-term operational efficiency. Conclusion: Merck's ( NYSE:MRK ) stellar Q4 results, fueled by Keytruda's exceptional sales performance and strategic initiatives, position the company for a decade of resilience in the face of impending challenges. The pharmaceutical giant's optimistic outlook, robust financials, and proactive measures to address patent exclusivity loss underscore its commitment to innovation, strategic partnerships, and sustained growth.